Clinical and immunological characteristics of newborn infants from mothers with cancers
Objective. To provide the clinical characteristics of the health status and to assess the immune status of neonates born to mothers with cancer who had received chemotherapy during pregnancy.Makieva M.I., Matveeva N.K., Vanko L.V., Tsoi T.A., Zhukova A.S., Shatalova E.A., Polushkina E.S., Averyanova M.V., Timofeeva L.A., Krechetova L.V., Zubkov V.V., Shmakov P.G.
Subjects and methods. Pregnant women with cancer (n = 60) and their newborn infants (n = 64) underwent physical examination. Ultrasonography was used to examine the brain, abdominal organs, kidneys, and heart in all the babies. Flow cytometry was employed to assess the composition of lymphocyte subpopulations in the umbilical cord blood of 27 newborn infants and in the venous blood of their mothers.
Results. The babies born to women with cancer had lower weight and height and higher frequency of complications in the early neonatal period, which can be attributed to a lower gestational age due to premature delivery that necessitated a more aggressive therapy in the mother. The signs that stemmed from imbalance in the cellular component of immunity, which were manifested by decreases in the immunoregulatory index and in the count of B lymphocytes and by increases in the level of activated T lymphocytes and in that of lymphocytes ready for apoptosis, were observed in pregnant women with cancer who had received immunosuppressive therapy. The umbilical cord blood of their newborn infants displayed a reduction in the relative content of B lymphocytes in the absence of significant differences in the number of T lymphocytes in the control group.
Conclusion. The satisfactory status of neonates, the course of the neonatal period, and the lack of considerable changes in the immune status of newborn infants from cancer mothers receiving chemotherapy may be indicative of the adequacy of the performed drug therapy necessary to suppress disease activity and to ensure a successful pregnancy.
Keywords
pregnancy
oncology
chemotherapy
newborn infant
immunity
Supplementary Materials
- Table 1. Clinical characteristics of newborns (М±SD)
- Table 2. Morbidity structure in newborns from mothers with breast cancer and myeloproliferative diseases
- Table 3. Immune status of pregnant women with oncological diseases, healthy pregnant women, and their newborns (M±SD)
References
1. Liu Y., Y. Liu, Wang Y., Chen X., Chen H., Zhang J. Malignancies associated with pregnancy: an analysis of 21 clinical cases. Irish. J. Med. Sci. 2015; 184(1): 175-81.
2. Pavlidis N. Cancer and pregnancy: what should we know about the management with systemic treatment of pregnant women with cancer? Eur. J. Cancer. 2011; 47(Suppl. 3): S348-52.
3. Паукер В.А., Шмаков Р.Г. Онкологические заболевания и беременность. Акушерство и гинекология. 2013; 11: 13-8. [Pauker W.A., Shmakov R.G. Cancer and pregnancy. Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2013; (11): 13-8. (in Russian)]
4. Córdoba O., Llurba E., Saura C., Rubio I., Ferrer Q., Cortés J., Xercavins J. Multidisciplinary approach to breast cancer diagnosed during pregnancy: Maternal and neonatal outcomes. Breast. 2013; 22(4): 515-9.
5. Ko E.M., Van Le L. Chemotherapy for gynecologic cancers occurring during pregnancy. Obstet. Gynecol. Surv. 2011; 66(5): 291-8.
6. Vandenbriele C., Dierickx D., Amant F., Delforge M. The treatment of hematologic malignancies in pregnancy. Facts Views Vis. Obgyn. 2010; 2(2): 74-87.
7. Córdoba O., Llurba E., Cortés J., Sabadell M.D., Lirola J.L., Ferrer Q. et al. Complete pathological remission in a patient with hormone-receptor positive and c-erbB-2 expression-negative breast cancer treated with FAC chemotherapy during pregnancy. Tumori. 2010; 96(4):629-32.
8. Brewer M., Kueck A., Runowicz C.D. Chemotherapy in pregnancy. Clin. Obstet. Gynecol. 2011; 54(4): 602-18.
9. Ives A.D., Saunders C.M., Semmens J.B. The Western Australian gestational breast cancer project: a population-based study of the incidence, management and outcomes. Breast. 2005; 14(4): 276-82.
10. Hahn K.M., Johnson P.H., Gordon N., Kuerer H., Middleton L., Ramirez M. et al. Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in utero. Cancer. 2006; 107(6):1219-26.
11. Murthy R.K., Theriault R.L., Barnett C.M., Hodge S., Ramirez M.M., Milbourne A. et al. Outcomes of children exposed in utero to chemotherapy for breast cancer. Breast Cancer Res. 2014; 16(6): 500.
12. Волочаева М.В., Шмаков Р.Г., Зубков В.В. Здоровье детей, рожденных женщинами с раком молочной железы, связанным с беременностью. Акушерство и гинекология. 2014; 7: 33-7. [Volochaeva M.V., Shmakov R.G., Zubkov V.V. The health of babies born to women with pregnancy-associated breast cancer. Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2014; (7): 33-7. (in Russian)]
13. Fenton T.R., Nasser R., Eliasziw M., Kim J.H., Bilan D., Sauve R. Validating the weight gain of preterm infants between the reference growth curve of the fetus and the term infant. BMC Pediatr. 2013; 13: 92.
14. Motta M., Ciardelli L., Marconi M., Tincani A., Gasparoni A., Lojacono A., Chirico G. Immune system development in infants born to mothers with autoimmune disease, exposed in utero to immunosuppressive agents. Am. J. Perinatol. 2007; 24(8): 441-7.
Received 04.09.2017
Accepted 22.09.2017
About the Authors
Makieva M.I., neonatologist, pediatrician, the head of the clinical work of the department of newborns, National Medical Research Center of Obstetrics, Gynecology, and Perinatology named after V.I. Kulakov, Ministry of Health of Russia. 117997, Russia, Moscow, Ac. Oparina str. 4. Tel.: +74954381183. Е-mail: m_makieva@oparina4.ruMatveeva N.K., candidate of biological science, senior researcher of clinical immunology laboratory, National Medical Research Center of Obstetrics, Gynecology, and Perinatology named after V.I. Kulakov, Ministry of Health of Russia. 117997, Russia, Moscow, Ac. Oparina str. 4. Tel.: +74954381183. Е-mail: matveeva_nk@mail.ru.
Vanko L.V., doctor of medicine, professor, leading research worker of clinical immunology laboratory, National Medical Research Center of Obstetrics, Gynecology, and Perinatology named after V.I. Kulakov, Ministry of Health of Russia. 117997, Russia, Moscow, Ac. Oparina str. 4. Tel.: +74954381183. Е-mail: lvanko@mail.ru
Tsoy T.A., neonatologist of National Medical Research Center of Obstetrics, Gynecology, and Perinatology named after V.I. Kulakov, Ministry of Health of Russia.
117997, Russia, Moscow, Ac. Oparina str. 4. Tel.: +74954381183. Е-mail: t_tsoy@oparina4.ru
Zhukova A.S., research worker of clinical immunology laboratory, National Medical Research Center of Obstetrics, Gynecology, and Perinatology named after V.I. Kulakov, Ministry of Health of Russia. 117997, Russia, Moscow, Ac. Oparina str. 4. Tel.: +74954381183. Е-mail: a_belyaeva@oparina4.ru
Shatalova E.A., neonatologist of National Medical Research Center of Obstetrics, Gynecology, and Perinatology named after V.I. Kulakov, Ministry of Health of Russia. 117997, Russia, Moscow, Ac. Oparina str. 4. Tel.: +74954381183. Е-mail: e_shatalova@oparina4.ru
Polushkina E.S., candidate of medicine sciences, obstetrician-gynecologist, National Medical Research Center of Obstetrics, Gynecology, and Perinatology named
after V.I. Kulakov, Ministry of Health of Russia. 117997, Russia, Moscow, Ac. Oparina str. 4. Tel.: +74954381183. Е-mail: e_polushkina@oparina4.ru
Averiyanova M.V., 6-year student of Pirogov Russian National Research Medical University.
117997, Russia, Moscow, Ostrovitianov str. 1. Tel.: +74954381183. Е-mail: marisha@mail.ru
Timofeeva L.A., candidate of medicine sciences, the head of the department of newborns, National Medical Research Center of Obstetrics, Gynecology, and Perinatology named after V.I. Kulakov, Ministry of Health of Russia.
117997, Russia, Moscow, Ac. Oparina str. 4. Tel.: +74954381183. Е-mail: leilatimofeeva@mail.ru, l_timofeeva@oparina4.ru
Krechetova L.V., candidate of medicine sciences, head of clinical immunology laboratory, National Medical Research Center of Obstetrics, Gynecology, and Perinatology named after V.I. Kulakov, Ministry of Health of Russia. 117997, Russia, Moscow, Ac. Oparina str. 4. Tel.: +74954381183. Е-mail: k_l_v_@mail.ru
Shmakov R.G., Doctor of Medicine, Head Physician, National Medical Research Center of Obstetrics, Gynecology, and Perinatology named after V.I. Kulakov,
Ministry of Health of Russia. 117997, Russia, Moscow, Ac. Oparina str. 4. Tel.: +74954381183. Е-mail: r_shmakov@oparina4.ru
Zubkov V.V., Doctor of Medicine, Head of the Department of Neonatology and Pediatrics, National Medical Research Center of Obstetrics, Gynecology, and Perinatology named after V.I. Kulakov, Ministry of Health of Russia; Professor of the Department of Neonatology, Federal State Autonomous Educational Institution of Higher Education, I.M. Sechenov First Moscow State Medical University of the Ministry of Health of Russia.
117997, Russia, Moscow, Ac. Oparina str. 4. Tel.: +74954381183. Е-mail: v_zubkov@oparina4.ru
For citations: Makieva M.I., Matveeva N.K., Vanko L.V., Tsoi T.A., Zhukova A.S., Shatalova E.A., Polushkina E.S., Averyanova M.V., Timofeeva L.A., Krechetova L.V., Zubkov V.V., Shmakov P.G. Clinical and immunological characteristics of newborn infants from mothers with cancers. Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2017; (11): 92-9. (in Russian)
https://dx.doi.org/10.18565/aig.2017.11.92-99
Similar Articles
